Standard

Lymphoma

HLA-DRB5 · rs4530903

Stands on its own. Nothing else here links to this position yet — but the page above is the point: what the research found, what each genotype means, and where it came from, in language you can read. Links to conditions, drugs and the senses appear automatically if we write them.

Strength of the evidence

1 / 4

Its strongest genetic-study result is p = 10⁻¹², with 5 associations in the GWAS Catalog.

How this is scored

4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10⁻⁵⁰. 2: ClinVar from one lab (1 star), or p ≤ 10⁻²⁰. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10⁻⁸). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.

What the study found

Who was studied 275 Follicular non-Hodgkin's Lymphoma cases, 269 diffuse large B-cell non-Hodgkin's Lymphoma cases, 198 other non-Hodgkin's Lymphoma cases, 202 Hodgkin's Lymphoma cases, 4,044 controls; replicated in 202 European ancestry Follicular non-Hodgkin's Lymphoma cases, 367 European ancestry diffuse large B-cell non-Hodgkin's Lymphoma cases, 577 European ancestry other non-Hodgkin's Lymphoma cases, 99 European ancestry Hodgkin's Lymphoma cases, 2,596 European ancestry controls.

The effect Each copy of the T allele carried 1.93 times the odds of Lymphoma; p = 3 × 10⁻¹².

Where it sits Chromosome 6, band 6p21.32 — between genes, 14.1 kb from HLA-DQA1.

How common each version is

CT

Korean KRGDB

C 93.4% · T 6.6%

Korean Korea4K

C 93.7% · T 6.3%

Japanese ToMMo

C 94.9% · T 5.1%

Vietnamese

C 99.5% · T 0.5%

World gnomAD

C 90.2% · T 9.8%

World 1000 Genomes

C 93.6% · T 6.4%

World TOPMed

C 91.0% · T 9.0%

By ancestry gnomAD

East Asian

C 98.3% · T 1.7%

European (non-Finnish)

C 89.0% · T 11.0%

African / African American

C 93.1% · T 6.9%

South Asian

C 96.2% · T 3.8%

Admixed American (Latino)

C 90.7% · T 9.3%

Middle Eastern

C 95.6% · T 4.4%

Finnish

C 79.9% · T 20.1%

Ashkenazi Jewish

C 87.0% · T 13.0%

The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.

What each result means

C/C No copy of the version the research linked to Lymphoma. This is the starting point the study compared everyone against.

C/T One copy of the version the research linked to Lymphoma. That is a smaller link than two copies.

T/T Two copies of the version the research linked to Lymphoma. That is the strongest link of the three results. A link in a study is not a diagnosis.

Source

Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies

Vijai J, Kirchhoff T, Schrader KA, Brown J, Dutra-Clarke AV, Manschreck C, Hansen N, Rau-Murthy R, Sarrel K, Przybylo J, Shah S, Cheguri S

and 13 more — show all

Stadler Z, Zhang L, Paltiel O, Ben-Yehuda D, Viale A, Portlock C, Straus D, Lipkin SM, Lacher M, Robson M, Klein RJ, Zelenetz A, Offit K

PLoS genetics · 2013 · PMID 23349640 · open access

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Lymphoma (rs4530903). MyGeneLog™. https://www.mygenelog.com/variants/rs4530903

← See all variants